Literature DB >> 30658724

Treating alcohol-related liver disease from a public health perspective.

Theresa Hydes1, William Gilmore2, Nick Sheron3, Ian Gilmore4.   

Abstract

Herein, we describe the evolving landscape of alcohol-related liver disease (ALD) including the current global burden of disease and cost to working-aged people in terms of death and disability, in addition to the larger spectrum of alcohol-related heath complications and its wider impact on society. We further review the most effective and cost-effective public health policies at both a population and individual level. Currently, abstinence is the only effective treatment for ALD, and yet because the majority of ALD remains undetected in the community abstinence is initiated too late to prevent premature death in the majority of cases. We therefore hope that this review will help inform clinicians of the "public health treatment options" for ALD to encourage engagement with policy makers and promote community-based hepatology as a speciality, expanding our patient cohort to allow early detection, and thereby a reduction in the enormous morbidity and mortality associated with this disease.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Alcohol; Policy; Public health

Mesh:

Year:  2019        PMID: 30658724     DOI: 10.1016/j.jhep.2018.10.036

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  13 in total

1.  Alcohol use and binge drinking among U.S. men, pregnant and non-pregnant women ages 18-44: 2002-2017.

Authors:  Deborah S Hasin; Dvora Shmulewitz; Katherine Keyes
Journal:  Drug Alcohol Depend       Date:  2019-09-27       Impact factor: 4.492

2.  Alcohol-related liver disease: Time for action.

Authors:  Ramon Bataller; Gavin E Arteel; Christophe Moreno; Vijay Shah
Journal:  J Hepatol       Date:  2019-02       Impact factor: 25.083

Review 3.  Role of mechanistic target of rapamycin in autophagy and alcohol-associated liver disease.

Authors:  Xiaojuan Chao; Sha Neisha Williams; Wen-Xing Ding
Journal:  Am J Physiol Cell Physiol       Date:  2022-09-05       Impact factor: 5.282

4.  Estimating alcohol-attributable liver disease mortality: A comparison of methods.

Authors:  Adam Sherk; Marissa B Esser; Tim Stockwell; Timothy S Naimi
Journal:  Drug Alcohol Rev       Date:  2022-04-01

Review 5.  Microbiota reprogramming for treatment of alcohol-related liver disease.

Authors:  Mohamed Tausif Siddiqui; Gail A M Cresci
Journal:  Transl Res       Date:  2020-07-17       Impact factor: 7.012

Review 6.  Liver specific, systemic and genetic contributors to alcohol-related liver disease progression.

Authors:  Bernd Schnabl; Gavin E Arteel; Felix Stickel; Jan Hengstler; Nachiket Vartak; Ahmed Ghallab; Steven Dooley; Yujia Li; Robert F Schwabe
Journal:  Z Gastroenterol       Date:  2022-01-18       Impact factor: 1.769

Review 7.  Cirrhotic patients and older people.

Authors:  Paul Carrier; Marilyne Debette-Gratien; Jérémie Jacques; Véronique Loustaud-Ratti
Journal:  World J Hepatol       Date:  2019-09-27

Review 8.  Public health policies and alcohol-related liver disease.

Authors:  Meritxell Ventura-Cots; Maria Pilar Ballester-Ferré; Samhita Ravi; Ramon Bataller
Journal:  JHEP Rep       Date:  2019-08-08

Review 9.  PNPLA3-A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease.

Authors:  Xiaocheng Charlie Dong
Journal:  Front Med (Lausanne)       Date:  2019-12-17

10.  Causes and trends in liver disease and hepatocellular carcinoma among men and women who received liver transplants in the U.S., 2010-2019.

Authors:  Sonia Wang; Mehlika Toy; Thi T Hang Pham; Samuel So
Journal:  PLoS One       Date:  2020-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.